Insilico Medicine Advances Garutadustat in Phase II Trial for IBD Treatment Insilico Medicine announces successful first dose in a Phase II trial for Garutadustat, aiming to treat Inflammatory Bowel Disease (IBD) efficiently.

Insilico Medicine Advances Garutadustat in Phase II Trial for IBD Treatment #United_States #Bethesda #IBD_treatment #Insilico_Medicine #Garutadustat